



September 23, 2026

Special Situations, LLC
% Mary G. Skelly
Associate Director, Regulatory Affairs
Lbria
1125 Boone Aire Rd.
Florence, KY 41042

Re: K260117
Trade/Device Name: Everslide
Regulation Number: 21 CFR§ 884.5300
Regulation Name: Condom
Regulatory Class: II
Product Code: NUC
Dated: August 21, 2026
Received: August 21, 2026

Dear Mary G. Skelly:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (<https://www.fda.gov/media/99812/download>) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (<https://www.fda.gov/media/99785/download>).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at <https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system>.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory->

[assistance/contact-us-division-industry-and-consumer-education-dice](#)) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Monica D. Garcia -S

Monica D. Garcia, Ph.D.

Assistant Director

DHT3B: Division of Reproductive,

Gynecology, and Urology Devices

OHT3: Office of Gastrorenal, ObGyn,

General Hospital, and Urology Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K260117

Device Name

Everslide

Indications for Use (Describe)

Everslide is a personal lubricant for penile and/or vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. This product is compatible with natural rubber latex and polyisoprene condoms. This product is not compatible with polyurethane condoms.

Type of Use (Select one or both, as applicable)

☐ Prescription Use (Part 21 CFR 801 Subpart D)

☒ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(K) SUMMARY
K260117
Everslide

1. Submitter Information

Special Situations LLC

321 South Boston Avenue, Suite 203, Tulsa, OK, USA 74103

Michael Frid, PhD

mfrid@specialsituationsllc.com

+1-(617)-306-1196

2. Submission Correspondent

Mary G. Skelly

Associate Director

Mary.Skelly@lbria.com

(973)-519-8694

3. Date Prepared

September 22, 2026

4. Device Identification

Device Name: Everslide

Common Name: Personal lubricant

Regulation Name: 21 CFR §884.5300

Regulation Name: Condom

Device Class: II

Product Code: NUC (Lubricant, Personal)

5. Predicate Device

Product Name: Uberlube

510(k) Number: K151647

The predicate device has not been subject to a design-related recall.

6. Device Description

Everslide is a non-sterile personal lubricant. It is silicone-based, available over the counter, and formulated to be clear-colored and with a slight lavender aroma. The subject device is compatible with natural rubber latex and lubricated polyisoprene male condoms. It is not compatible with polyurethane male condoms.

The formulation consists of dimethicone and dimethiconol, dimethicone, olive squalane, tocopheryl Acetate (Vitamin E), *Hippophae Rhamnoides* Seed Oil (sea buckthorn oil), and *Lavandula Angustifolia* (Lavender) Oil.

The device is neither a contraceptive nor a spermicide. The device is packaged in a pre-filled aluminum barrier laminate (ABL) bottle (70ml) with a pump.

7. Indications for Use

Everslide is a personal lubricant for penile and/or vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. This product is compatible with natural rubber latex and polyisoprene condoms. This product is not compatible with polyurethane condoms.

8. Comparison of Intended Use and Technological Characteristics with the Predicate Device

The table below compares the intended use and technological characteristics of the subject and predicate device.

Characteristic/Feature	Everslide (K260117)	Uberlube (K151647)
Indications for Use	Everslide is a personal lubricant for penile and/or vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. This product is compatible with natural rubber latex and polyisoprene condoms. This product is not compatible with polyurethane condoms.	Uberlube is a personal lubricant, for penile and/or vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. This product is compatible with natural rubber latex and polyisoprene condoms. This product is not compatible with polyurethane condoms.
Formulation	Dimethicone and dimethiconol, dimethicone, olive squalane, tocopheryl Acetate (Vitamin E), <i>Hippophae Rhamnoides</i> Seed Oil (sea buckthorn oil), and <i>Lavandula Angustifolia</i> (Lavender) Oil	Dimethicone dimethiconol, cyclomethicone, and tocopheryl Acetate (Vitamin E)
Rx/OTC	OTC	OTC
Sterile	No	No
Base type	Silicone	Silicone
Appearance/Color	Clear viscous gel	Clear and colorless
Odor	None to slight lavender aroma	Characteristic
Viscosity	80 – 300 cPs	280 cSt

Characteristic/Feature	Everslide (K260117)	Uberlube (K151647)
Antimicrobial Effectiveness Tested per USP <62>	Absent	Absent
Total mold/yeast count (TYMC) per USP <61>	≤ 10 CFU/g	≤ 10 CFU/g
Total aerobic microbial count (TAMC) per USP <61>	≤ 10 CFU/g	≤ 10 CFU/g
Antimicrobial Effectiveness Testing (USP<51> Category 2)	Yes	Yes
Condom Compatibility	Compatible with Natural Rubber Latex and Polyisoprene Condoms. It is incompatible with lubricated polyurethane male condoms.	Compatible with Natural Rubber Latex and Polyisoprene Condoms. It is incompatible with lubricated polyurethane male condoms.
Shelf Life	1 year	3 years

The subject device and predicate device have the same indications for use and intended use - to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. The subject device and predicated devices differ in formulation, and shelf-life. These differences in technological characteristics do not raise different questions of safety and effectiveness.

9. Summary of Non-Clinical Performance Testing

Biocompatibility

Biocompatibility studies were performed in accordance with the 2020 FDA Guidance Document, *Use of International Standard ISO 10993-1, "Biological Evaluation of Medical Devices-Part 1: Evaluation and testing within a risk management process."*

The following testing was conducted:

- a. Cytotoxicity (ISO 10993-5:2009)
- b. Sensitization (ISO 10993-10:2010)
- c. Vaginal Irritation (ISO 10993-10:2010)
- d. Acute Systemic Toxicity (ISO 10993-11:2017)

The test results demonstrated that the subject device is non-cytotoxic, non-sensitizing, non-irritating, and non-systemically toxic.

Condom Compatibility

The subject device was tested for compatibility with natural rubber latex, polyisoprene, and polyurethane condoms in accordance with the ASTM D7661-18, *Standard Test Method for Determining Compatibility of Personal Lubricants with Natural Rubber Latex Condoms*. The results show that Everslide is compatible with natural rubber latex and polyisoprene male condoms and is not compatible with lubricated polyurethane male condoms.

Shelf Life

The subject device has a shelf-life of one-year based on the results of an accelerated aging study per ASTM F1980-21. The shelf-life study evaluated all device specifications listed in Table 1 and met all device specifications throughout the stated shelf-life.

10. Conclusions

The results of performance testing described above demonstrate that Everslide is as safe and effective as the predicate device and supports a determination of substantial equivalence.